
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current SHTDF market cap is 3.09B. The company's latest EPS is CNY 6.7474 and P/E is 0.34.
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
Total Revenue | 425.27B | 456.41B | 521.05B | 552.15B | 596.57B |
Operating Income | 19.21B | 20.51B | 21.9B | 24.22B | 24B |
Net Income | 6.25B | 7.19B | 7.76B | 8.53B | 9.05B |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
Total Assets | 269.89B | 311.24B | 335.41B | 364.78B | 383.39B |
Total Liabilities | 192.95B | 221.29B | 235.76B | 254.71B | 263.08B |
Total Equity | 76.94B | 89.95B | 99.65B | 110.07B | 120.32B |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
Operating | 18.78B | 11.15B | 9.31B | 20.96B | 17.17B |
Investing | -6.8B | -2.2B | -1.27B | -3.59B | -944.54M |
Financing | -13.08B | 2.03B | -14.69B | -5.69B | -7.64B |
Market Cap | 3.09B |
Price to Earnings Ratio | 0.34 |
Price to Sales Ratio | 0.01 |
Price to Cash Ratio | 0.05 |
Price to Book Ratio | 0.03 |
Dividend Yield | - |
Shares Outstanding | 1.34B |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 500 |
52 Week Change | -22.03% |
52 Week High | 2.95 |
52 Week Low | 1.97 |
Spread (Intraday) | 0.48 (17.27%) |
Company Name | Sinopharm Group Co Ltd (PK) |
Address |
6th floor, no. 221 fuzhou road shanghai 200002 |
Website | https://www.sinopharmgroup.com.cn |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions